NCT01632826Approved For MarketingNot Applicable
A Multicenter, Single-Arm, Open-Label Treatment Use Protocol for Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Approved For Marketing
- Sponsor
- Celgene
- Locations
- 1
Study Overview
Brief Summary
To provide pomalidomide access to relapsed/refractory multiple myeloma subjects with a likelihood of benefit from the pomalidomide treatment while the medication is not commercially available
Detailed Description
Several clinical studies indicate that pomalidomide has activity in relapsed and refractory multiple myeloma with response rates ranging between 30% and 60% at pomalidomide doses at 2 mg/day and/or 4 mg/day.
Study Design
- Study Type
- Expanded Access
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Must have documented diagnosis of relapsed or relapsed/refractory multiple myeloma and have measurable disease (serum or urine M-protein)
- •Age ≥ 18 years
- •Must have had at least ≥ 2 prior anti-myeloma therapies
- •Must have received at least 2 consecutive cycles of both lenalidomide and bortezomib, either alone or in combination
- •Must have failed treatment with the last lenalidomide-containing regimen and the last bortezomib-containing regimen
- •Must have documented disease progression during or after the last antimyeloma regimen
- •Females of childbearing potential (FCBP) must agree to utilize two reliable forms of contraception simultaneously or practice complete abstinence from heterosexual contact for at least 28 days before starting drug, while participating in the study and for at least 28 days after study treatment discontinuation.
- •Males must agree to use a latex condom during sexual contact with FCBP while participating in the study and for 28 days following discontinuation from study treatment.
Exclusion Criteria
- •Peripheral Neuropathy ≥ Grade 2
- •Non-secretory multiple myeloma
- •Previous therapy with pomalidomide
- •Use of any investigational agents within 28 days or 5 half lives (whichever is longer) of initiating study treatment
- •Subjects with conditions requiring chronic steroid or immunosuppressive treatment.
- •Hypersensitivity to thalidomide, lenalidomide or dexamethasone
- •Known Human Immunodeficiency Virus positive, active or chronic Hepatitis A, B or C
- •Pregnant or breastfeeding females
- •Unacceptable hematological or biochemical laboratory abnormalities
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 4
A Multiple Myeloma Trial in Patients With Bone MetastasesMultiple MyelomaNCT00104104Novartis Pharmaceuticals179
Completed
Phase 2
Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and CyclophosphamideRelapsed or Refractory Multiple MyelomaNCT02046915University Hospital Tuebingen60
Completed
Phase 3
Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)Crohn's DiseaseNCT00338650Abbott1,000
Completed
Phase 3
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple MyelomaMultiple MyelomaNCT01324947Celgene74
Terminated
Phase 3
Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance TreatmentMultiple MyelomaNCT03440411Fondazione EMN Italy Onlus9